Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A Agilent reported well. top and bottom beats. Guidance a bit tame.
Market likes it!
AGILENT TECHNOLOGIES INC
$153.80 +8.655 (+5.96%)
https://stockcharts.com/h-sc/ui?s=A
A Agilent Technologies Q4 EPS $1.53 Beats $1.39 Estimate, Sales $1.85B Beat $1.76B Estimate
https://stockcharts.com/h-sc/ui?s=A
By Benzinga — 4:12 PM ET 11/21/22
Agilent Technologies (NYSE:A) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.39 by 10.07 percent. This is a 26.45 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $1.85 billion which beat the analyst consensus estimate of $1.76 billion by 5.11 percent. This is a 11.45 percent increase over sales of $1.66 billion the same period last year.
0
No worries,,,you are on the freight train accumulation and revving for investors for a liftoff....billion share volume days coming soon....this is a pink current stock and possible billions of dollars in the pipeline.
How embarrassing lol
And I just posted on the wrong board, Very sorry, lol.
Proactive Investors is a S C A M. Have you guys even looked into the PR this thing has been getting for a year? This is a scam.
Agilent Technologies strong into earnings
We will be looking for a long into earnings depending on the market behavior today. The company is expected to beat earnings and revenues easily and the chart points to further gains if the $74 range can hold.
Average Analysts recommendation BUY
Average Price target $88
Hey guys, I have some new DD for you on the Board Members and what they may possibly be doing:
https://twitter.com/KitKuhlman/status/1116043756623392768
can you copy n paste that e mail..
You can buy an empty shell for more money than our market cap. Major potential upside here
Sometimes it is not what is said that is important but rather what is not said..
Today's press release:
This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study.
Notice they stated that the AHA has NOT yet seen the results of the study. Notice that it did not state that Amarin hasn't seen it like JT has said in the past. To push to present at the AHA w/ knowledge of the result is a positive as they would not be in a hurry if it was negative. Also, you can not provide advanced access to the results if you don't have it. You'd simply say we still do not have the results.
Essentially we know they have the results. The question is whether they completely understand it and that is the sole reason why it has not been PR'ed yet. I could be reading into something that isn't there or wasn't intentional but the way its written subtly implies they have it and by PR'ing their push to present it asap, reflects what is likely a positive outcome.
BECAUSE this is a POS!!!
why is this board dead? just dropped a big chuck of change in here, go baby go!
I emailed WEWI. They confirmed the contract for $250,000,000.
And that's being nice - these igiots are the annoying cockroaches of the otc
Quit whining....
yup, we just have to lean in, as the fb lady said.
u said it,sky is the limit
Wow, what a run.
Good morning Fibanotch. Good to see another on the job!
MG
Agilent Tech trading above its fair value before reporting earnings:
Fair Value
AMMJ getting crushed in these final minutes. Shame :[ hopefully tomorrow turns around. I'm down a small amount but I have to cut my losses if people continue to dump.
A Agilent Tops 2Q Views, Raises Full-Year Forecast -- Market Talk
BY Dow Jones & Company, Inc. — 4:39 PM ET 05/16/2016
http://stockcharts.com/h-sc/ui?s=a
Agilent's (A) 2Q adjusted EPS and sales surpass Wall Street's expectations, as the laboratory-equipment maker also raises earnings and revenue guidance for the full year. A beat the sales consensus for all three of its divisions, with the largest--Life Sciences and Applied Markets Group--garnering $495M versus the $476M analysts predicted. LSAG is the unit that provides a majority of the company's instrumentation and software for analytical labs. Cowen recently said demand from the pharmaceutical sector remains robust. A shares are up 3.6% at $44.49 in after-hours trading, and through today's close, are up 25% from a February low. (patrick.sheridan@wsj.com)
(END) Dow Jones Newswires
05-16-16 1639ET
ER Play A
I'm in
http://stockcharts.com/h-sc/ui?s=A
MAY 16 A to announce Q2 earnings After Market (Confirmed)